Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px
Document › Details

Oryzon Genomics S.A.. (10/26/18). "Press Release: Oryzon Raises EUR 13 Million through a Private Placement with US and European Investors [Not for US, CA, AU, JP, ZA or any other jurisdiction where unlawful]". Madrid & Cambridge, MA.

Region Region EUR(WEST)+AM(NORTH)
Organisations Organisation Oryzon Genomics S.A. (Madrid Stock Exchange: ORY)
  Group Oryzon Genomics (Group)
  Organisation 2 Roth Capital Partners LLC
Products Product LSD1 inhibitor (Lysine Specific Demethylase-1 inhibitor)
  Product 2 investment banking
Index term Index term Oryzon Genomics–SEVERAL: investment, 201810 private placement €13m w 4.96m new common shares at €2.62/share
Person Person Buesa, Carlos (Oryzon Genomics SA 201404 CEO + Co-Founder)
     


   
Record changed: 2018-11-03

Advertisement

Picture [iito] – Putting Information into Context 600x102px

More documents for Oryzon Genomics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px




» top